ID

23807

Description

Fluorouracil and Leucovorin Plus Either Irinotecan or Oxaliplatin With or Without Cetuximab in Treating Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum https://clinicaltrials.gov/ct2/show/NCT00077233

Lien

https://clinicaltrials.gov/ct2/show/NCT00077233

Mots-clés

  1. 27/08/2012 27/08/2012 -
  2. 14/07/2017 14/07/2017 - Martin Dugas
Téléchargé le

14 juillet 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Metastatic Colorectal Cancer Fluorouracil Leucovorin Irinotecan Oxaliplatin NCT00077233 CALGB 80203

No Instruction available.

  1. StudyEvent: CALGB: 80203 DERMATOLOGY SPECIFIC QUALITY-OF-LIFE QUESTIONNAIRE (DSQL)
    1. No Instruction available.
Header
Description

Header

Alias
UMLS CUI-1
C1320722
Patient Initials
Description

Patient Initials

Type de données

text

Alias
UMLS CUI [1]
C2986440
Patient Hospital No.
Description

Patient Hospital Number

Type de données

text

Alias
UMLS CUI [1]
C0421459
Institution/Affiliate
Description

Institution/Affiliate

Type de données

text

Alias
UMLS CUI [1]
C1301943
Participating Group
Description

Participating Group

Type de données

text

Alias
UMLS CUI [1]
C2347449
Participating Group Protocol No.
Description

Participating Group Protocol Number

Type de données

text

Alias
UMLS CUI [1,1]
C3274381
UMLS CUI [1,2]
C2347449
Participating Group Patient ID
Description

Participating Group Patient ID

Type de données

text

Alias
UMLS CUI [1]
C2348585
CALGB Study No.
Description

CALGB Study Number

Type de données

text

Alias
UMLS CUI [1,1]
C3274381
UMLS CUI [1,2]
C1516238
CALGB Patient ID
Description

CALGB Patient ID

Type de données

text

Alias
UMLS CUI [1,1]
C2348585
UMLS CUI [1,2]
C1516238
Are data amended
Description

Data amended

Type de données

boolean

Alias
UMLS CUI [1]
C1691222
Cetuximab Skin Toxicities
Description

Cetuximab Skin Toxicities

Alias
UMLS CUI-1
C0995188
UMLS CUI-2
C1167791
Mark with an X if there are none
Description

No adverse event

Type de données

boolean

Alias
UMLS CUI [1]
C1963761
MedDRA
Description

MedDRA

Type de données

text

Alias
UMLS CUI [1]
C1140263
Adverse event term
Description

Adverse event term

Type de données

integer

Alias
UMLS CUI [1]
C2826934
Other, specify
Description

Other,specify

Type de données

text

Alias
UMLS CUI [1]
C3845569
Adverse event grade
Description

Adverse event grade

Type de données

integer

Alias
UMLS CUI [1]
C2985911
Cetuximab Dose Modification
Description

Cetuximab Dose Modification

Type de données

integer

Alias
UMLS CUI [1,1]
C0995188
UMLS CUI [1,2]
C1707811
Adverse event onset date
Description

Adverse event onset date

Type de données

date

Alias
UMLS CUI [1]
C2985916
Adverse event end date
Description

Adverse event end date

Type de données

date

Alias
UMLS CUI [1]
C2697886
If ongoing mark with an X
Description

Adverse event ongoing

Type de données

boolean

Alias
UMLS CUI [1]
C2826663
Completed by
Description

Completed by

Type de données

text

Alias
UMLS CUI [1]
C1550483
Date form originally completed
Description

Date form originally completed

Type de données

date

Alias
UMLS CUI [1]
C1549507

Similar models

No Instruction available.

  1. StudyEvent: CALGB: 80203 DERMATOLOGY SPECIFIC QUALITY-OF-LIFE QUESTIONNAIRE (DSQL)
    1. No Instruction available.
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Header
C1320722 (UMLS CUI-1)
Patient Initials
Item
Patient Initials
text
C2986440 (UMLS CUI [1])
Patient Hospital Number
Item
Patient Hospital No.
text
C0421459 (UMLS CUI [1])
Institution/Affiliate
Item
Institution/Affiliate
text
C1301943 (UMLS CUI [1])
Participating Group
Item
Participating Group
text
C2347449 (UMLS CUI [1])
Participating Group Protocol Number
Item
Participating Group Protocol No.
text
C3274381 (UMLS CUI [1,1])
C2347449 (UMLS CUI [1,2])
Participating Group Patient ID
Item
Participating Group Patient ID
text
C2348585 (UMLS CUI [1])
CALGB Study Number
Item
CALGB Study No.
text
C3274381 (UMLS CUI [1,1])
C1516238 (UMLS CUI [1,2])
CALGB Patient ID
Item
CALGB Patient ID
text
C2348585 (UMLS CUI [1,1])
C1516238 (UMLS CUI [1,2])
Data amended
Item
Are data amended
boolean
C1691222 (UMLS CUI [1])
Item Group
Cetuximab Skin Toxicities
C0995188 (UMLS CUI-1)
C1167791 (UMLS CUI-2)
No adverse event
Item
Mark with an X if there are none
boolean
C1963761 (UMLS CUI [1])
MedDRA
Item
MedDRA
text
C1140263 (UMLS CUI [1])
Item
Adverse event term
integer
C2826934 (UMLS CUI [1])
Code List
Adverse event term
CL Item
Rash/desquamation (1)
C1559142 (UMLS CUI-1)
CL Item
Pruritus (2)
C0033774 (UMLS CUI-1)
CL Item
Erythema multiforme (3)
C0014742 (UMLS CUI-1)
CL Item
Nail changes (4)
C0234909 (UMLS CUI-1)
CL Item
Dry skin (5)
C0151908 (UMLS CUI-1)
CL Item
Other, specify (6)
C3845569 (UMLS CUI-1)
Other,specify
Item
Other, specify
text
C3845569 (UMLS CUI [1])
Item
Adverse event grade
integer
C2985911 (UMLS CUI [1])
Code List
Adverse event grade
CL Item
1 (1)
CL Item
2 (2)
CL Item
3 (3)
CL Item
4 (4)
CL Item
5 (5)
Item
Cetuximab Dose Modification
integer
C0995188 (UMLS CUI [1,1])
C1707811 (UMLS CUI [1,2])
Code List
Cetuximab Dose Modification
CL Item
Dose held (1)
C0178602 (UMLS CUI-1)
C0549178 (UMLS CUI-2)
CL Item
Dose reduced (2)
C1707814 (UMLS CUI-1)
CL Item
Drug discontinued (3)
C0558681 (UMLS CUI-1)
Adverse event onset date
Item
Adverse event onset date
date
C2985916 (UMLS CUI [1])
Adverse event end date
Item
Adverse event end date
date
C2697886 (UMLS CUI [1])
Adverse event ongoing
Item
If ongoing mark with an X
boolean
C2826663 (UMLS CUI [1])
Completed by
Item
Completed by
text
C1550483 (UMLS CUI [1])
Date form originally completed
Item
Date form originally completed
date
C1549507 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial